文献速递胸部肿瘤

肺癌PD-L1免疫组化检测方法:Blueprint PD-L1免疫组化检测方法比较项目第一阶段结果

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
PubMed 文献 · J Thorac Oncol · 2016-11-29

Blueprint PD-L1免疫组化检测方法比较项目为产业-学术合作,比较四种临床试验所用PD-L1免疫组化检测方法(22C3、28-8、SP142和SP263)在39例非小细胞肺癌肿瘤中的分析和临床可比性。结果显示22C3、28-8和SP263在肿瘤细胞染色上接近,而SP142染色的肿瘤细胞总体较少;免疫细胞染色变异性高于肿瘤细胞染色。互换检测方法和截断值会导致部分患者PD-L1状态被「错误分类」,需要更多数据来指导替代染色检测方法的使用。

要点

  • 22C3、28-8和SP263三种PD-L1免疫组化检测方法在肿瘤细胞染色上接近,SP142染色的肿瘤细胞总体较少。
  • 四种检测方法均显示免疫细胞染色,但免疫细胞染色的变异性高于肿瘤细胞染色。
  • 互换检测方法和截断值会导致部分患者PD-L1状态被「错误分类」。

核心结论

  • 四种检测方法中三种在肿瘤细胞染色上密切一致,而第四种(SP142)染色的肿瘤细胞持续较少。
  • 所有检测方法均显示免疫细胞染色,但变异性高于肿瘤细胞染色。
  • 尽管三种检测方法对PD-L1表达的分析性能相似,互换检测方法和截断值会导致部分患者PD-L1状态被「错误分类」。
  • 需要更多数据来指导基于不同特定治疗相关PD-L1截断值的替代染色检测方法的使用。

研究设计与样本

  • BluePrint PD-L1免疫组化检测方法比较项目为产业-学术合作项目。
  • 共39例非小细胞肺癌肿瘤用四种PD-L1免疫组化检测方法(22C3、28-8、SP142和SP263)染色,与临床试验中所用方法一致。
  • 三位专家独立评估各自检测方法下肿瘤细胞和免疫细胞任何强度染色阳性的百分比。
  • 通过比较患者高于和低于选定表达截断值的分类以及使用不同检测方法和截断值组合的一致性来评估临床诊断性能。

主要发现

  • 使用22C3、28-8和SP263检测方法时,PD-L1染色肿瘤细胞的百分比相当,而SP142检测方法总体上显示较少的染色肿瘤细胞。
  • 四种检测方法间免疫细胞染色的变异性似乎高于肿瘤细胞染色。
  • 38例中19例(50.0%)被分类为高于所有检测方法选定截断值,5例(13%)被分类为低于所有检测方法选定截断值。
  • 38例中14例(37%)会根据所使用的检测方法/评分系统而做出不同的PD-L1分类。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多数据来指导基于不同特定治疗相关PD-L1截断值的替代染色检测方法的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The Blueprint Programmed Death Ligand 1 (PD-L1) Immunohistochemistry (IHC) Assay Comparison Project is an industrial-academic collaborative partnership to provide information on the analytical and clinical comparability of four PD-L1 IHC assays used in clinical trials. METHODS: A total of 39 NSCLC tumors were stained with four PD-L1 IHC assays (22C3, 28-8, SP142, and SP263), as used in the clinical trials. Three experts in interpreting their respective assays independently evaluated the percentages of tumor and immune cells staining positive at any intensity. Clinical diagnostic performance was assessed through comparisons of patient classification above and below a selected expression cutoff and by agreement using various combinations of assays and cutoffs. RESULTS: Analytical comparison demonstrated that the percentage of PD-L1-stained tumor cells was comparable when the 22C3, 28-8, and SP263 assays were used, whereas the SP142 assay exhibited fewer stained tumor cells overall. The variability of immune cell staining across the four assays appears to be higher than for tumor cell staining. Of the 38 cases, 19 (50.0%) were classified above and five (13%) were classified below the selected cutoffs of all assays. For 14 of the 38 cases (37%), a different PD-L1 classification would be made depending on which assay/scoring system was used. CONCLUSIONS: The Blueprint PD-L1 IHC Assay Comparison Project revealed that three of the four assays were closely aligned on tumor cell staining whereas the fourth showed consistently fewer tumor cells stained. All of the assays demonstrated immune cell staining, but with greater variability than with tumor cell staining. By comparing assays and cutoffs, the study indicated that despite similar analytical performance of PD-L1 expression for three assays, interchanging assays and cutoffs would lead to "misclassification" of PD-L1 status for some patients. More data are required to inform on the use of alternative staining assays upon which to read different specific therapy-related PD-L1 cutoffs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2016. PMID: 27913228. doi:10.1016/j.jtho.2016.11.2228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。